Wyeth CEO Touts Nutritionals As Major Player Along Health Care “Continuum”
This article was originally published in The Tan Sheet
Executive Summary
Infant formula may not spark investors' interest as much as cutting-edge pharmaceuticals, but it is fueling Wyeth's growth in emerging markets, President and CEO Bernard Poussot says
You may also be interested in...
Wyeth Nutritionals: Pfizer’s New MVP, Or Benchwarmer?
Wyeth Nutrition could boost Pfizer's revenue outside the U.S. and buffer some upcoming patent losses in its prescription roster through the pending $68 billion deal
Wyeth Nutritionals: Pfizer’s New MVP, Or Benchwarmer?
Wyeth Nutrition could boost Pfizer's revenue outside the U.S. and buffer some upcoming patent losses in its prescription roster through the pending $68 billion deal
Wyeth Nutritionals: Pfizer’s New MVP, Or Benchwarmer?
Wyeth Nutrition could boost Pfizer's revenue outside the U.S. and buffer some upcoming patent losses in its prescription roster through the pending $68 billion deal